Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term erythromycin in stable COPD: airway microbiome and exacerbation prevention
ChiCTR2000033816Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic obstructive pulmonary disease (COPD) comparing oral erythromycin with Control: oral placebo (2 arms). Primary endpoint: Sputum microbiome. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
erythromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2000033816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033816.